How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
74
NUS Quote, Financials, Valuation and Earnings
Last price:
$10.80
Seasonality move
:
4.88%
Day range:
$10.46 - $10.92
52-week range:
$5.32 - $14.62
Dividend yield:
2.22%
P/E ratio:
4.97x
P/S ratio:
0.35x
P/B ratio:
0.66x
Volume:
525.4K
Avg. volume:
443K
1-year change:
66.31%
Market cap:
$527M
Revenue:
$1.7B
EPS (TTM):
$2.18
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Nu Skin Enterprises, Inc. has -30.62% downside to fair value with a price target of $7.50 per share.
NUS vs. S&P 500
-
Over the past 5 trading days, Nu Skin Enterprises, Inc. has overperformed the S&P 500 by 1.98% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Nu Skin Enterprises, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nu Skin Enterprises, Inc. revenues have been falling on a year-over-year basis for 17 quarters in a row. In the most recent quarter Nu Skin Enterprises, Inc. reported revenues of $364.2M.
Earnings Growth
-
Nu Skin Enterprises, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Nu Skin Enterprises, Inc. reported earnings per share of $0.34.
Enterprise value:
565.4M
EV / Invested capital:
--
Price / LTM sales:
0.35x
EV / EBIT:
9.36x
EV / Revenue:
0.36x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
10.60x
Price / Operating cash flow:
10.12x
Enterprise value / EBITDA:
4.86x
Gross Profit (TTM):
$1B
Return On Assets:
7.5%
Net Income Margin (TTM):
7.02%
Return On Equity:
14.81%
Return On Invested Capital:
9.82%
Operating Margin:
5.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2B | $1.8B | $1.6B | $430.1M | $364.2M | |
| Gross Profit | $1.4B | $1.3B | $1B | $301.5M | $256.7M | |
| Operating Income | $87.8M | $84M | $60.4M | $18.2M | $21.6M | |
| EBITDA | $205.4M | $154.7M | $116.2M | $35.6M | $33.7M | |
| Diluted EPS | $1.17 | -$2.08 | $2.18 | $0.17 | $0.34 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $890.9M | $777.8M | $701.1M | $653.4M | $548.1M | |
| Total Assets | $2B | $1.8B | $1.8B | $1.6B | $1.4B | |
| Current Liabilities | $540.6M | $365.5M | $434M | $339.4M | $254.4M | |
| Total Liabilities | $1B | $921.2M | $970.9M | $876M | $624.6M | |
| Total Equity | $936.5M | $841.9M | $822.2M | $706.9M | $799.8M | |
| Total Debt | $484.3M | $502.9M | $571.1M | $501.8M | $291.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $90M | $140.1M | $89.5M | $31.4M | $27.5M | |
| Cash From Investing | -$132.5M | -$39.7M | $166.8M | -$6.5M | -$9.9M | |
| Cash From Financing | -$19.8M | -$109.8M | -$227.5M | -$28.8M | -$26.9M | |
| Free Cash Flow | $38.1M | $90.7M | $53.4M | $22.8M | $17.6M | |
NUS
Sector
Market Cap
$527M
$110.1M
Price % of 52-Week High
73.94%
75.48%
Dividend Yield
2.22%
0%
Shareholder Yield
11.77%
2.42%
1-Year Price Total Return
66.31%
-2.54%
Beta (5-Year)
1.012
0.246
Dividend yield:
2.22%
Annualized payout:
$0.24
Payout ratio:
17.67%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$10.48
200-day SMA
Buy
Level
$9.69
Bollinger Bands (100)
Buy
Level
9.85 - 11.41
Chaikin Money Flow
Buy
Level
1.1M
20-day SMA
Buy
Level
$10.76
Relative Strength Index (RSI14)
Buy
Level
55.06
ADX Line
Buy
Level
17.65
Williams %R
Neutral
Level
-44.1379
50-day SMA
Buy
Level
$10.35
MACD (12, 26)
Buy
Level
2.88
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.3695)
Buy
CA Score
(Annual)
Level (-0.1402)
Buy
Beneish M-Score
(Annual)
Level (-3.614)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (0.5555)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nu Skin Enterprises, Inc. is a holding company, which engages in the development and distribution of beauty and wellness solutions. It operates through the following segments: Mainland China, Americas, South Korea, Southeast Asia/Pacific, EMEA, Japan, Hong Kong/Taiwan, Nu Skin Other, Manufacturing, and Rhyz Other. The company was founded by Blake M. Roney, Sandra N. Tillotson, and Steven J. Lund in 1984 and is headquartered in Provo, UT.
Stock Forecast FAQ
In the current month, NUS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NUS average analyst price target in the past 3 months is $7.50.
-
Where Will Nu Skin Enterprises, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nu Skin Enterprises, Inc. share price will drop to $7.50 per share over the next 12 months.
-
What Do Analysts Say About Nu Skin Enterprises, Inc.?
Analysts are divided on their view about Nu Skin Enterprises, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nu Skin Enterprises, Inc. is a Sell and believe this share price will rise from its current level to $7.50.
-
What Is Nu Skin Enterprises, Inc.'s Price Target?
The price target for Nu Skin Enterprises, Inc. over the next 1-year time period is forecast to be $7.50 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NUS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nu Skin Enterprises, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NUS?
You can purchase shares of Nu Skin Enterprises, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nu Skin Enterprises, Inc. shares.
-
What Is The Nu Skin Enterprises, Inc. Share Price Today?
Nu Skin Enterprises, Inc. was last trading at $10.80 per share. This represents the most recent stock quote for Nu Skin Enterprises, Inc.. Yesterday, Nu Skin Enterprises, Inc. closed at $10.81 per share.
-
How To Buy Nu Skin Enterprises, Inc. Stock Online?
In order to purchase Nu Skin Enterprises, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NUS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NUS
Sector
P/E ratio
4.97x
17.65x
PEG ratio
-0.01x
0.12x
P/B ratio
0.66x
1.51x
Price / LTM sales
0.35x
0.52x
Growth Metrics
NUS
Sector
Revenue growth
-15.33%
2.79%
Earnings growth
103.42%
2.3%
Revenue (5-year growth)
-6.47%
3.36%
Earnings forecast
$0.30
$0.26
Profitability
NUS
Sector
Profitability FY 2024
$1.2B
$254.9M
Return on invested capital
9.82%
4.33%
Return on assets
7.5%
3.03%
Return on equity
14.81%
7.7%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Feb
5
Balance Sheet
NUS
Sector
Total cash
$253M
$85.8M
Short term investments
$11.1M
$31.1M
Total assets
$1.5B
$1.1B
Long term debt
$291.4M
$5.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
